研究発表実績 京都大学 島津 裕 Ann Hematol. 2024 Aug 21. doi: 10.1007/s00277-024-05934-2.Online ahead of print.
The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patients.
論文報告
研究発表実績 研究発表実績 京都大学 島津 裕 Cancer Immunology, Immunotherapy.2024 May 17;73(7):135.
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients
研究発表実績 京都大学 中村直和 Ann Hematol.2024 Mar 16.doi:10.1007/s00277-024-05705-z.Online ahead of print.
Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab:a multicenter retrospective study
研究発表実績 大阪医療センター 中谷 綾 Leuk Res Rep.2023 Nov 17:20:100395.
Impact of cytogenetic abnormalities in symptomatic multiple myeloma;a Japanese real-world analysis from Kansai Myeloma ...
研究発表実績 京都府立医科大学 志村勇司 Int Hematol. 2023 Nov;118(5):609-617.
Real-world data of induction therapies for patients with transplant-ineligible newly diagnosed multiple myeloma:Retrosp...
研究発表実績 京都大学 島津 裕 Sci Rep.2023 Mar 29;13(1):5159.
Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobuli...
研究発表実績 京都大学 島津 裕 Ther Adv Hematol.2022 Dec 13;13:20406207221142487.
Monocyte or white blood cell counts and β2 microglobulin predict the durable efficacy of daratumumab with lenalidomide
研究発表実績 京都大学 恩田佳幸 Ther Adv Hematol.2022 Jun 24;13:20406207221104584.
Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone andcarfilzomib-dexamethasone in ...
研究発表実績 大阪医療センター 中谷 綾 EJHaem. 2021 Oct 20;2(4):765-773.
Significance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma:A multicenter retrospective analysis...
研究発表実績 大阪市立大学 高桑輝人 Hematol Oncol. 2021 Aug;39(3):349-357.
Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myeloma